Xeris Biopharma (XERS) Earnings Date, Estimates & Call Transcripts $3.23 +0.01 (+0.31%) (As of 11/1/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Xeris Biopharma Latest Earnings SummaryUpcoming Q3 Earnings DateNov. 8Before Market OpensConfirmedActual EPS (Aug. 8) -$0.10 Beat By $0.01 Consensus EPS (Aug. 8) -$0.11 Xeris Biopharma announced Q2 2024 earnings on August 8, 2024, reporting an EPS of -$0.10, which topped the consensus estimate of -$0.11 by $0.01. Quarterly revenue was reported to be $48.07 million, above the consensus estimate of $46.80 million. With a trailing EPS of -$0.43, Xeris Biopharma's earnings are expected to grow next year, from ($0.40) to ($0.25) per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseXERS Upcoming EarningsXeris Biopharma's next earnings date is scheduled for Friday, November 8, 2024, with a conference call scheduled for at 8:30 AM ET. Interested parties can register for or listen to the call or dial in at 866-813-9403 with passcode "906920". Get Xeris Biopharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xeris Biopharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataXERS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.XERS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Xeris Biopharma Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.14-$0.11-$0.13Q2 20242-$0.11-$0.11-$0.11Q3 20242-$0.12-$0.10-$0.11Q4 20242-$0.08-$0.07-$0.08FY 20248($0.45)($0.39)($0.42) Xeris Biopharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/8/2024(Confirmed)------- 8/8/2024Q2 2024-$0.11-$0.10+$0.01-$0.10$46.80M$48.07M 5/9/2024Q1 2024-$0.12-$0.14 -$0.02-$0.14$41.56M$40.64M 3/6/2024Q4 2023-$0.09-$0.10 -$0.01-$0.10$45.50M$44.39M 11/9/2023Q3 2023-$0.12-$0.09+$0.03-$0.09$40.93M$48.32M 8/8/2023Q2 2023-$0.13-$0.14 -$0.01-$0.14$34.84M$38.01M 5/9/2023Q1 2023-$0.17-$0.12+$0.05-$0.12$30.77M$33.20M Get the Latest News and Ratings for XERS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. 3/8/2023Q4 2022-$0.16-$0.10+$0.06-$0.10$31.04M$33.14M 11/9/2022Q3 2022-$0.17-$0.14+$0.03-$0.12$29.12M$29.73M Xeris Biopharma Earnings - Frequently Asked Questions When is Xeris Biopharma's earnings date? Xeris Biopharma has confirmed that its next quarterly earnings data will be published on Friday, November 8th, 2024. Learn more on XERS's earnings history. What guidance has Xeris Biopharma issued on next quarter's earnings? Xeris Biopharma updated its FY 2024 earnings guidance on Thursday, August, 8th. The company issued revenue guidance of $190.0 million-$200.0 million, compared to the consensus revenue estimate of $187.4 million. Did Xeris Biopharma beat their earnings estimates last quarter? In the previous quarter, Xeris Biopharma (NASDAQ:XERS) reported ($0.10) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.11) by $0.01. Learn more on analysts' earnings estimate vs. XERS's actual earnings. How can I listen to Xeris Biopharma's earnings conference call? The conference call for Xeris Biopharma's latest earnings report can be listened to online. Listen to Conference Call How can I read Xeris Biopharma's conference call transcript? The conference call transcript for Xeris Biopharma's latest earnings report can be read online. Read Transcript How much revenue does Xeris Biopharma generate each year? Xeris Biopharma (NASDAQ:XERS) has a recorded annual revenue of $163.91 million. How much profit does Xeris Biopharma generate each year? Xeris Biopharma (NASDAQ:XERS) has a recorded net income of -$62.26 million. XERS has generated -$0.43 earnings per share over the last four quarters. What is Xeris Biopharma's EPS forecast for next year? Xeris Biopharma's earnings are expected to grow from ($0.40) per share to ($0.25) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies VERU Earnings HRMY Earnings ARVN Earnings TARS Earnings RXRX Earnings CNTA Earnings GLPG Earnings NRIX Earnings SYRE Earnings WVE Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to RunBank of America Earnings Uncover Shifts in Consumer Spending 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here This page (NASDAQ:XERS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
